JP2023509880A5 - - Google Patents

Info

Publication number
JP2023509880A5
JP2023509880A5 JP2022538928A JP2022538928A JP2023509880A5 JP 2023509880 A5 JP2023509880 A5 JP 2023509880A5 JP 2022538928 A JP2022538928 A JP 2022538928A JP 2022538928 A JP2022538928 A JP 2022538928A JP 2023509880 A5 JP2023509880 A5 JP 2023509880A5
Authority
JP
Japan
Application number
JP2022538928A
Other languages
Japanese (ja)
Other versions
JPWO2021129658A5 (https=
JP2023509880A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2020/138598 external-priority patent/WO2021129658A1/zh
Publication of JP2023509880A publication Critical patent/JP2023509880A/ja
Publication of JP2023509880A5 publication Critical patent/JP2023509880A5/ja
Publication of JPWO2021129658A5 publication Critical patent/JPWO2021129658A5/ja
Priority to JP2024127939A priority Critical patent/JP2024167222A/ja
Pending legal-status Critical Current

Links

JP2022538928A 2019-12-24 2020-12-23 加齢黄斑変性の治療における融合タンパク質の使用 Pending JP2023509880A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024127939A JP2024167222A (ja) 2019-12-24 2024-08-02 加齢黄斑変性の治療における融合タンパク質の使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201911346311.2 2019-12-24
CN201911346311 2019-12-24
CN202011441025 2020-12-11
CN202011441025.7 2020-12-11
PCT/CN2020/138598 WO2021129658A1 (zh) 2019-12-24 2020-12-23 融合蛋白在治疗年龄相关性黄斑变性中的应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024127939A Division JP2024167222A (ja) 2019-12-24 2024-08-02 加齢黄斑変性の治療における融合タンパク質の使用

Publications (3)

Publication Number Publication Date
JP2023509880A JP2023509880A (ja) 2023-03-10
JP2023509880A5 true JP2023509880A5 (https=) 2023-06-05
JPWO2021129658A5 JPWO2021129658A5 (https=) 2023-06-05

Family

ID=76575187

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022538928A Pending JP2023509880A (ja) 2019-12-24 2020-12-23 加齢黄斑変性の治療における融合タンパク質の使用
JP2024127939A Pending JP2024167222A (ja) 2019-12-24 2024-08-02 加齢黄斑変性の治療における融合タンパク質の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024127939A Pending JP2024167222A (ja) 2019-12-24 2024-08-02 加齢黄斑変性の治療における融合タンパク質の使用

Country Status (8)

Country Link
US (1) US20230056821A1 (https=)
EP (1) EP4082559A4 (https=)
JP (2) JP2023509880A (https=)
CN (2) CN118750581A (https=)
AU (2) AU2020414152B2 (https=)
CA (1) CA3165887A1 (https=)
TW (2) TWI879855B (https=)
WO (1) WO2021129658A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118718181A (zh) 2019-06-05 2024-10-01 里珍纳龙药品有限公司 用于精确剂量递送的装置及方法
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
CN117467025B (zh) * 2023-12-28 2024-04-16 上海鼎新基因科技有限公司 一种抗vegf和补体双功能融合蛋白及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014013205A2 (pt) * 2011-12-01 2020-10-27 Protevobio, Inc. proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
CN104940926B (zh) * 2014-09-25 2017-09-22 信达生物制药(苏州)有限公司 重组融合蛋白制剂
CN105435222B (zh) * 2014-09-25 2018-05-29 信达生物制药(苏州)有限公司 重组融合蛋白制剂

Similar Documents

Publication Publication Date Title
JP2023509880A5 (https=)
BR202020002392U2 (https=)
CN305531110S (https=)
CN306904022S (https=)
CN306249376S (https=)
CN306434686S (https=)
CN306431124S (https=)
CN306397373S (https=)
CN306277717S (https=)
CN306137204S (https=)
CN305536127S (https=)
CN305530396S (https=)
CN306101935S (https=)
CN305534529S (https=)
CN305534243S (https=)
CN305533467S (https=)
CN305533252S (https=)
CN305532875S (https=)
CN306463764S (https=)
CN306470037S (https=)
CN305532741S (https=)
CN306129215S (https=)
CN305531597S (https=)
CN305531438S (https=)
CN306442881S (https=)